These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6600652)

  • 1. Alterations in erythrocyte adenine nucleotide pools resulting from 2'-deoxycoformycin therapy.
    Koller CA; Mitchell BS
    Cancer Res; 1983 Mar; 43(3):1409-14. PubMed ID: 6600652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
    Yu AL; Bakay B; Kung FH; Nyhan WL
    Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia.
    Poplack DG; Sallan SE; Rivera G; Holcenberg J; Murphy SB; Blatt J; Lipton JM; Venner P; Glaubiger DL; Ungerleider R; Johns D
    Cancer Res; 1981 Sep; 41(9 Pt 1):3343-6. PubMed ID: 6973390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of adenosine triphosphate catabolism induced by deoxyadenosine and by nucleoside analogues in adenosine deaminase-inhibited human erythrocytes.
    Bontemps F; Van den Berghe G
    Cancer Res; 1989 Sep; 49(18):4983-9. PubMed ID: 2788493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy.
    Grever MR; Siaw MF; Jacob WF; Neidhart JA; Miser JS; Coleman MS; Hutton JJ; Balcerzak SP
    Blood; 1981 Mar; 57(3):406-17. PubMed ID: 6970050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
    Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
    Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of cutaneous T cell lymphoma with 2'-deoxycoformycin (pentostatin).
    Dang-Vu AP; Olsen EA; Vollmer RT; Greenberg ML; Hershfield MS
    J Am Acad Dermatol; 1988 Oct; 19(4):692-8. PubMed ID: 3263401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deoxycoformycin-induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non-replicating lymphocytes.
    Kefford RF; Fox RM
    Br J Haematol; 1982 Apr; 50(4):627-36. PubMed ID: 6978147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical consequences of treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Paine RM; Smyth JF; Harrap KR
    Adv Exp Med Biol; 1979; 122B():365-71. PubMed ID: 317569
    [No Abstract]   [Full Text] [Related]  

  • 10. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
    Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity and immunosuppressive activity of binary combinations of 2'-deoxycoformycin and 2'-deoxyadenosine.
    Paine RM; Weston BJ; Clink HM; Kohn J; Neville AM; McGhee KG; Harrap KR
    Cancer Treat Rep; 1981; 65(3-4):259-66. PubMed ID: 6972254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deoxyadenosine triphosphate accumulation in erythrocytes of deoxycoformycin-treated mice.
    Smith CM; Henderson JF
    Biochem Pharmacol; 1982 Apr; 31(8):1545-51. PubMed ID: 6980005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia.
    Venner PM; Glazer RI; Blatt J; Sallan S; Rivera G; Holcenberg JS; Lipton J; Murphy SB; Poplack DG
    Cancer Res; 1981 Nov; 41(11 Pt 1):4508-11. PubMed ID: 6975654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATP depletion as a consequence of adenosine deaminase inhibition in man.
    Siaw MF; Mitchell BS; Koller CA; Coleman MS; Hutton JJ
    Proc Natl Acad Sci U S A; 1980 Oct; 77(10):6157-61. PubMed ID: 6969403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Successful treatment with 2'-deoxycoformycin in a case of adult T-cell leukemia].
    Ishii M; Yamaguchi K; Yul LS; Oda T; Takatsuki K
    Rinsho Ketsueki; 1986 May; 27(5):780-3. PubMed ID: 3018324
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of RNA synthesis by deoxyadenosine plus deoxycoformycin in resting lymphocytes.
    Matsumoto SS; Yu J; Yu AL
    J Immunol; 1983 Dec; 131(6):2762-6. PubMed ID: 6196398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of hairy cell leukemia (HCL) with pentostatin (2'-deoxycoformycin, dCF).
    Spiers AS; Parekh SJ
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():173-5. PubMed ID: 2653498
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of pentostatin (2'-deoxycoformycin, dCF) in the management of lymphoproliferative malignancies.
    Spiers AS
    Blood Rev; 1987 Jun; 1(2):106-10. PubMed ID: 3332090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipyridamole enhancement of toxicity to L1210 cells by deoxyadenosine and deoxycoformycin combinations in vitro.
    Kang GJ; Kimball AP
    Cancer Res; 1984 Feb; 44(2):461-6. PubMed ID: 6362851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of 5'-nucleotidase activity and antileukemic effect in 2'-deoxycoformycin therapy.
    Wortmann RL; Holcenberg J; Poplack DG
    Cancer Treat Rep; 1982 Feb; 66(2):387-90. PubMed ID: 6275991
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.